Market Cap 82.81M
Revenue (ttm) 0.00
Net Income (ttm) -28.85M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 679,200
Avg Vol 920,396
Day's Range N/A - N/A
Shares Out 34.65M
Stochastic %K 69%
Beta 1.26
Analysts Strong Sell
Price Target $11.67

Company Profile

Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration in the United States. The company's lead product candidate is Buntanetap, which is in phase 3 to treat alzheimer's disease, as well as in open-label phase 3 to treat parkinson's disease. It also develops ANVS405, which is in phase 2 and 3 clinical trials for the treatment of traumatic brain injury and/or stroke; and ANVS301, which finished phase 1 clinical trial developed to increase cognitive ca...

Industry: Biotechnology
Sector: Healthcare
Phone: 484 875 3192
Address:
101 Lindenwood Drive, Suite 225, Malvern, United States
KY3000
KY3000 May. 12 at 10:34 PM
$ANVS Annovis Bio director buys 713,800 shares at $2.10 | ANVS Insider Trading https://www.stocktitan.net/sec-filings/ANVS/form-4-annovis-bio-inc-insider-trading-activity-a6627085d5a1.html
0 · Reply
Alex1710
Alex1710 May. 12 at 9:21 PM
$ANVS I think one day a clinical trial that would combine buntanetap and Bla 2-73 could worth it. Reducing neurotoxic proteins and restores impaired autophagy could bring impressive results especially with a good safety profile. Just my opinion.
0 · Reply
LongOrShortToMakeMoney
LongOrShortToMakeMoney May. 12 at 8:27 PM
$ANVS nice move today
1 · Reply
CoffeeRocks
CoffeeRocks May. 12 at 12:29 PM
1 · Reply
CoffeeRocks
CoffeeRocks May. 12 at 11:09 AM
0 · Reply
Dopamineaddict
Dopamineaddict May. 12 at 10:58 AM
$ANVS $ANVS offers a massive asymmetric risk/reward setup. Thank the $SAVA data manipulation scandal for the discount. When Cassava settled with the SEC, algorithms punished the entire small-cap Alzheimer's space. But look at the fundamental difference in the science. SAVA relied on a mechanism (Filamin A) the broader scientific community never supported, backed by contested western blots. A total black box. ANVS is built on universally validated biology: inhibiting the translation of known neurotoxic proteins (Tau and Amyloid). It is a measurable, well-documented mechanism of action. Scarred by SAVA, the market prices ANVS for failure, completely ignoring their 100% pure p-Tau217 Phase 3 cohort. Sector trauma has created a massive mispricing in an asset with verifiable targets.
5 · Reply
Dopamineaddict
Dopamineaddict May. 11 at 9:39 PM
$ANVS The market is heavily mispricing this because algorithms automatically discount "subgroup" data. But if you cross-reference the AD and PD trials, the biological math is undeniable. The current Ph3 AD trial is stacking the deck: screening ONLY for p-Tau217+ patients to guarantee a 100% pure cohort. Wall Street's biggest fear? That the massive 3.3 pt cognitive pop seen in the Ph2 AD trial at 3 months will fade by month 6 (Duration Risk). Here is the catalyst everyone missed: Look at the recent PD trial. In the PDD cohort with confirmed amyloid/tau pathology, buntanetap successfully defended the cognitive baseline against placebo for a full 6 MONTHS. This neutralizes the "statistical fluke" argument. The exact same biological subset (tau+) across two different disease labels showed the exact same cognitive benefit. The PD data explicitly de-risks the 6-month duration timeline for the current AD pivotal. Massive asymmetric setup.
1 · Reply
Dopamineaddict
Dopamineaddict May. 11 at 7:08 PM
$ANVS For their current, 760-patient Phase 3 trial (NCT06709014), Annovis completely overhauled their enrollment strategy. They instituted a mandatory gatekeeper: Patients must be positive for plasma p-Tau217. What is p-Tau217? It is currently the "gold standard" blood biomarker for Alzheimer's. It operates as a biological lie detector. If a patient is positive for p-Tau217, it is a virtual mathematical certainty that their brain is actively generating toxic amyloid and tau plaques. How it Stacks the Deck: By forcing every single patient to pass the p-Tau217 test before entering the trial, Annovis is systematically eliminating the 30% of misdiagnosed patients that ruined their last data set. They are guaranteeing a "pure" Alzheimer's cohort. By ensuring 100% of the trial participants actually possess the exact toxic proteins that buntanetap targets, Annovis is artificially—and legally—inflating the Probability of Success (POS) for hitting their primary cognitive endpoint (ADAS-Cog13).
1 · Reply
doyoujetset
doyoujetset May. 11 at 2:28 PM
$ANVS 1 year of sideways price action. Institutional ownership rising along with cash. Pay to play with Wallstreet. Weekly is setup again⏳
1 · Reply
Dopamineaddict
Dopamineaddict May. 11 at 11:42 AM
$ANVS sTREM2 (Microglial Activation): Reduced by a massive 43% in treated PD patients (Phase 2a). sTREM2 is a direct measure of microglial distress. • GFAP (Astrocyte Reactivity): Reduced by 28% in treated PD patients (Phase 2a). • YKL-40 (CHI3L1): Dropped by 55% in PD patients (Phase 2a, though slightly missed statistical significance) and also showed significant reductions in early Mild Cognitive Impairment (MCI) cohorts. YKL-40 is a heavily watched inflammatory marker expressed by astrocytes during acute neurological distress. • The Cytokine Panel (April 2026 Update): In the peer-reviewed Phase 2/3 AD publication that just dropped, biomarker analyses revealed broad systemic reductions across a whole panel of neuroinflammation markers, specifically: IL-5, IL-6, S100A12, IFN-γ, and IGF1R.
0 · Reply
Latest News on ANVS
Annovis Bio secures U.S. patent for buntanetap

2026-04-02T11:54:03.000Z - 5 weeks ago

Annovis Bio secures U.S. patent for buntanetap


Annovis Bio enters partnership with NeuroRPM

2026-03-19T11:56:46.000Z - 7 weeks ago

Annovis Bio enters partnership with NeuroRPM


Annovis Bio sees cash runway to 3Q26

2026-03-16T11:41:50.000Z - 2 months ago

Annovis Bio sees cash runway to 3Q26


Annovis Bio reports FY25 EPS ($1.40) vs. ($2.31) last year

2026-03-16T11:35:20.000Z - 2 months ago

Annovis Bio reports FY25 EPS ($1.40) vs. ($2.31) last year


Annovis to Host Corporate Update Webinar on January 28, 2026

Dec 16, 2025, 8:00 AM EST - 5 months ago

Annovis to Host Corporate Update Webinar on January 28, 2026


Annovis Announces Two Presentations at the CTAD 2025 Conference

Nov 24, 2025, 8:00 AM EST - 6 months ago

Annovis Announces Two Presentations at the CTAD 2025 Conference


Annovis announces FDA meeting to discuss PDD program

2025-11-18T14:39:45.000Z - 6 months ago

Annovis announces FDA meeting to discuss PDD program


Annovis Bio reports Q3 EPS (37c) vs. (97c) last year

2025-11-12T13:11:18.000Z - 6 months ago

Annovis Bio reports Q3 EPS (37c) vs. (97c) last year


Annovis Bio sees cash runway to 3Q26

2025-11-12T13:10:52.000Z - 6 months ago

Annovis Bio sees cash runway to 3Q26


Annovis Bio appoints Guerin as Chief Financial Officer

2025-09-25T11:35:16.000Z - 8 months ago

Annovis Bio appoints Guerin as Chief Financial Officer


Annovis Appoints Mark Guerin as Chief Financial Officer

Sep 25, 2025, 7:30 AM EDT - 8 months ago

Annovis Appoints Mark Guerin as Chief Financial Officer


Annovis Completes Full Patent Transfer to Crystal Buntanetap

Aug 7, 2025, 8:00 AM EDT - 9 months ago

Annovis Completes Full Patent Transfer to Crystal Buntanetap


Annovis to Attend the AAIC 2025 with Four Poster Presentations

Jun 26, 2025, 8:00 AM EDT - 11 months ago

Annovis to Attend the AAIC 2025 with Four Poster Presentations


Annovis Bio Transcript: Status Update

Jun 24, 2025, 4:30 PM EDT - 11 months ago

Annovis Bio Transcript: Status Update


Annovis Bio rises 16.3%

2025-06-24T16:06:38.000Z - 11 months ago

Annovis Bio rises 16.3%


Annovis Bio says NYSE accepted plan to regain compliance

2025-06-19T10:35:07.000Z - 11 months ago

Annovis Bio says NYSE accepted plan to regain compliance


Annovis to Host Webinar and Live Q&A on June 24, 2025

Jun 5, 2025, 8:00 AM EDT - 1 year ago

Annovis to Host Webinar and Live Q&A on June 24, 2025


Annovis Bio Appoints Hui Liu as Director of Biostatistics

Apr 29, 2025, 8:00 AM EDT - 1 year ago

Annovis Bio Appoints Hui Liu as Director of Biostatistics


Annovis to Host Patients' Live Forum on February 27, 2025

Feb 19, 2025, 8:30 AM EST - 1 year ago

Annovis to Host Patients' Live Forum on February 27, 2025


Annovis Bio, Inc. Announces Proposed Public Offering

Jan 31, 2025, 8:14 PM EST - 1 year ago

Annovis Bio, Inc. Announces Proposed Public Offering


/C O R R E C T I O N -- Today's Marketplace/

Dec 4, 2024, 2:21 PM EST - 1 year ago

/C O R R E C T I O N -- Today's Marketplace/


KY3000
KY3000 May. 12 at 10:34 PM
$ANVS Annovis Bio director buys 713,800 shares at $2.10 | ANVS Insider Trading https://www.stocktitan.net/sec-filings/ANVS/form-4-annovis-bio-inc-insider-trading-activity-a6627085d5a1.html
0 · Reply
Alex1710
Alex1710 May. 12 at 9:21 PM
$ANVS I think one day a clinical trial that would combine buntanetap and Bla 2-73 could worth it. Reducing neurotoxic proteins and restores impaired autophagy could bring impressive results especially with a good safety profile. Just my opinion.
0 · Reply
LongOrShortToMakeMoney
LongOrShortToMakeMoney May. 12 at 8:27 PM
$ANVS nice move today
1 · Reply
CoffeeRocks
CoffeeRocks May. 12 at 12:29 PM
1 · Reply
CoffeeRocks
CoffeeRocks May. 12 at 11:09 AM
0 · Reply
Dopamineaddict
Dopamineaddict May. 12 at 10:58 AM
$ANVS $ANVS offers a massive asymmetric risk/reward setup. Thank the $SAVA data manipulation scandal for the discount. When Cassava settled with the SEC, algorithms punished the entire small-cap Alzheimer's space. But look at the fundamental difference in the science. SAVA relied on a mechanism (Filamin A) the broader scientific community never supported, backed by contested western blots. A total black box. ANVS is built on universally validated biology: inhibiting the translation of known neurotoxic proteins (Tau and Amyloid). It is a measurable, well-documented mechanism of action. Scarred by SAVA, the market prices ANVS for failure, completely ignoring their 100% pure p-Tau217 Phase 3 cohort. Sector trauma has created a massive mispricing in an asset with verifiable targets.
5 · Reply
Dopamineaddict
Dopamineaddict May. 11 at 9:39 PM
$ANVS The market is heavily mispricing this because algorithms automatically discount "subgroup" data. But if you cross-reference the AD and PD trials, the biological math is undeniable. The current Ph3 AD trial is stacking the deck: screening ONLY for p-Tau217+ patients to guarantee a 100% pure cohort. Wall Street's biggest fear? That the massive 3.3 pt cognitive pop seen in the Ph2 AD trial at 3 months will fade by month 6 (Duration Risk). Here is the catalyst everyone missed: Look at the recent PD trial. In the PDD cohort with confirmed amyloid/tau pathology, buntanetap successfully defended the cognitive baseline against placebo for a full 6 MONTHS. This neutralizes the "statistical fluke" argument. The exact same biological subset (tau+) across two different disease labels showed the exact same cognitive benefit. The PD data explicitly de-risks the 6-month duration timeline for the current AD pivotal. Massive asymmetric setup.
1 · Reply
Dopamineaddict
Dopamineaddict May. 11 at 7:08 PM
$ANVS For their current, 760-patient Phase 3 trial (NCT06709014), Annovis completely overhauled their enrollment strategy. They instituted a mandatory gatekeeper: Patients must be positive for plasma p-Tau217. What is p-Tau217? It is currently the "gold standard" blood biomarker for Alzheimer's. It operates as a biological lie detector. If a patient is positive for p-Tau217, it is a virtual mathematical certainty that their brain is actively generating toxic amyloid and tau plaques. How it Stacks the Deck: By forcing every single patient to pass the p-Tau217 test before entering the trial, Annovis is systematically eliminating the 30% of misdiagnosed patients that ruined their last data set. They are guaranteeing a "pure" Alzheimer's cohort. By ensuring 100% of the trial participants actually possess the exact toxic proteins that buntanetap targets, Annovis is artificially—and legally—inflating the Probability of Success (POS) for hitting their primary cognitive endpoint (ADAS-Cog13).
1 · Reply
doyoujetset
doyoujetset May. 11 at 2:28 PM
$ANVS 1 year of sideways price action. Institutional ownership rising along with cash. Pay to play with Wallstreet. Weekly is setup again⏳
1 · Reply
Dopamineaddict
Dopamineaddict May. 11 at 11:42 AM
$ANVS sTREM2 (Microglial Activation): Reduced by a massive 43% in treated PD patients (Phase 2a). sTREM2 is a direct measure of microglial distress. • GFAP (Astrocyte Reactivity): Reduced by 28% in treated PD patients (Phase 2a). • YKL-40 (CHI3L1): Dropped by 55% in PD patients (Phase 2a, though slightly missed statistical significance) and also showed significant reductions in early Mild Cognitive Impairment (MCI) cohorts. YKL-40 is a heavily watched inflammatory marker expressed by astrocytes during acute neurological distress. • The Cytokine Panel (April 2026 Update): In the peer-reviewed Phase 2/3 AD publication that just dropped, biomarker analyses revealed broad systemic reductions across a whole panel of neuroinflammation markers, specifically: IL-5, IL-6, S100A12, IFN-γ, and IGF1R.
0 · Reply
Dopamineaddict
Dopamineaddict May. 11 at 11:41 AM
$ANVS 2. Neurodegeneration & Axonal Integrity When you stop the toxic proteins from forming, the physical damage to the neurons should slow down. We measure this via NfL (the exact same biomarker AB Science is relying on). • NfL (Neurofilament Light Chain): * In the Phase 2a trials, NfL dropped by 13% in AD patients and 9% in PD patients (though Annovis noted the study wasn't sufficiently powered at the time for this specific readout to hit hard statistical significance). • However, in their massive peer-reviewed Phase 2/3 AD results published just last month (April 2026), they confirmed further robust reductions in NfL, pointing directly to potential disease-modifying activity.
0 · Reply
Dopamineaddict
Dopamineaddict May. 11 at 11:39 AM
$ANVS IN summary: These are the primary proteins buntanetap is actively blocking from being synthesized. • p-Tau (Phosphorylated Tau): Showed a 12% reduction in AD patients (Phase 2a). • Aβ42 (Amyloid Beta 42): Showed a massive 51.4% reduction trend in the CSF of patients (Phase 2a, p=0.0533). It also significantly reduced APP (Amyloid Precursor Protein) cleavage fragments sAPPα and β. • Total Tau (t-Tau): Showed statistically significant reductions in plasma in the Phase 2/3 AD trial, confirming the drug prevents the overall accumulation of tau, not just the phosphorylated form. • TDP-43: In their Phase 2/3 AD data (and highlighted heavily in their Q4 2023 update and April 2026 Nature NPJ Dementia publication), buntanetap achieved a statistically significant drop in TDP-43. This is highly notable, as TDP-43 is correlated with impaired axonal transport and nerve cell death
1 · Reply
zshortcut
zshortcut May. 11 at 2:27 AM
$ANVS institutions increasing positions.
0 · Reply
AIIAAIIA_88
AIIAAIIA_88 May. 9 at 8:25 PM
$ANVS A readout soon? PD AD home run or strike out?
1 · Reply
LongOrShortToMakeMoney
LongOrShortToMakeMoney May. 9 at 7:45 PM
$ANVS short it
1 · Reply
KY3000
KY3000 May. 8 at 5:53 PM
$ANVS very dangerous short. Stock hasn’t pulled back going into a presentation. I don’t think anyone covering
1 · Reply
ILikeDaStocks
ILikeDaStocks May. 8 at 5:49 PM
$ANVS Input regarding the following question is greatly appreciated. Are you aware of a company with -realistic potential- (two key words) of producing similar returns in the following 24 months as seen here with Annovis Bio -IF- the two P3 trials, presently being conducted, conclude successfully? Aka: whole number multiples of 1,000% (excluding 0 and 1 😂) from where we sit now at $2.30/share. ↗️
2 · Reply
ILikeDaStocks
ILikeDaStocks May. 8 at 3:38 PM
$ANVS Short interest in ANVS appears up substantially in the past few weeks, but the stock price is also up 30ish% since April 15. We are unaware of the financial backing behind the shorts, but we know they eventually cover. They are aware that substantial news in the next few months is unlikely, so they play, but their risk increases with time. Of course, without them or if they are squeezed, the stock price goes much higher. In companies I have great faith in, I enjoy taking full advantage of the actions of shorts as they keep prices low while I accumulate. Obviously in the market, dollars are made buying low and selling high, which is the same for the shorts but in reverse. Time tells who ultimately wins here in ANVS, but (IMO) I view the longs as heavily favored. ↗️
0 · Reply
zshortcut
zshortcut May. 8 at 2:15 PM
$ANVS they did there previous studies and found that the best results came from people with specific protein's. still a large percentage of the AD patients. now they're doing phase 3 with only people with the specific protein's how do you think the results will be?
0 · Reply
Martylevitt
Martylevitt May. 8 at 1:00 PM
$ANVS New study reveals fish oil supplements resulting in cognitive decline | 9 News Australia https://share.google/BMgmxkSkXoK6nTaJY
0 · Reply
SocioCobb
SocioCobb May. 7 at 10:13 PM
$ANVS I can not get Hoffman’s 1.5 million dollar open market buy out of my head. I mean, come on… insider makes such a significant commitment. Give me a bear argument. Please!
2 · Reply
uphillclimb13
uphillclimb13 May. 7 at 8:53 PM
$ANVS Buntanetap gains ground in new Alzheimer’s trial results Biotech May 04, 2026 https://longevity.technology/news/buntanetap-gains-ground-in-new-alzheimers-trial-results/
0 · Reply